Most biotech prospect lists are a spreadsheet of company names sorted by size. That is not a prospect list. That is a phone book, and it is why your outreach converts at two percent.
The flaw in how these lists get built
The typical approach: pull every biotech in a therapeutic area above a certain size, load them into the CRM, divide by rep, start dialing.
The problem is that this list treats a company that raised $200M last week identically to one that is quietly running out of money and will not buy anything from anyone this year. Both are “prospects.” Only one is actually in the market.
Company attributes tell you who could buy. Only events tell you who is about to.
Sort by timing, not by size
A useful list is organized around buying windows. The top of it should be companies where something recently happened that creates a need for what you sell:
- Raised significant capital in the last 90 days
- Announced a clinical milestone or phase transition
- Made an acquisition or were acquired
- Appointed a new executive in a function relevant to you
- Have an approaching regulatory date
Everything else goes below the line, to be nurtured, not called. Your reps’ time is finite, and it should be spent on the companies with a live reason to talk.
Add the two fields that actually matter
Most CRMs track company, contact, and stage. Add two more:
The trigger: what happened, and when. This is the reason for the call and the first line of the email.
The window: how long you have. A funding round gives you roughly a quarter. A leadership change gives you ninety days. An approaching PDUFA gives you until launch planning locks. After that, the opportunity closes whether you called or not.
These two fields turn a static list into a queue with urgency, which is the difference between prospecting and just having names.
The maintenance problem
Here is why most teams never do this: a trigger-based list decays fast. Events happen weekly, windows close, and the list has to be rebuilt continuously.
Doing that by hand means someone monitoring funding announcements, trial registries, regulatory calendars and executive appointments across the whole industry, every week, forever. That is a full-time job that nobody has time for, so the list quietly reverts to alphabetical, and outreach reverts to noise.
Know who to call
Your reps are calling companies in alphabetical order while their competitors are calling the ones that just raised. Sort the list by timing and the conversion rate takes care of itself.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
How should a biotech prospect list be organized?
By buying window rather than company size. Company attributes tell you who could buy, but only events tell you who is about to. The top of the list should be companies where something recently happened, such as a funding round, clinical milestone, acquisition, leadership change or approaching regulatory date, that creates a need.
What fields should a life sciences BD list include?
Beyond company, contact and stage, add two: the trigger (what happened and when, which becomes the reason for the call and the first line of the email) and the window (how long you have, since a funding round gives roughly a quarter and a leadership change about ninety days). These turn a static list into a queue with urgency.
Why do most biotech prospect lists fail?
Because they treat a company that raised $200M last week identically to one quietly running out of money. Both look like prospects, but only one is in the market. Trigger-based lists work far better but decay fast, requiring continuous monitoring of funding, trials, regulatory events and appointments, which most teams cannot sustain.
